237 related articles for article (PubMed ID: 33914193)
21. Glutamic acid decarboxylase antibodies in neurocritical patients: a culprit or a bystander?
Wang D; Huang K; Lin Z; Zhang Y; Liu G; Wu Y; Wang S
Neurol Sci; 2020 Dec; 41(12):3691-3696. PubMed ID: 32514855
[TBL] [Abstract][Full Text] [Related]
22. Anti-GAD antibodies in a cohort of neuropsychiatric patients.
Vinke AM; Schaper FLWVJ; Vlooswijk MCG; Nicolai J; Majoie MHJM; Martinez Martinez P; Hoffmann C; Damoiseaux JGMC; Rouhl RPW
Epilepsy Behav; 2018 May; 82():25-28. PubMed ID: 29579551
[TBL] [Abstract][Full Text] [Related]
23. Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition.
Daw K; Ujihara N; Atkinson M; Powers AC
J Immunol; 1996 Jan; 156(2):818-25. PubMed ID: 8543838
[TBL] [Abstract][Full Text] [Related]
24. Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity.
Rakocevic G; Raju R; Dalakas MC
Arch Neurol; 2004 Jun; 61(6):902-4. PubMed ID: 15210528
[TBL] [Abstract][Full Text] [Related]
25. T-cell reactivity to glutamic acid decarboxylase in stiff-man syndrome and cerebellar ataxia associated with polyendocrine autoimmunity.
Costa M; Saiz A; Casamitjana R; Castañer MF; Sanmartí A; Graus F; Jaraquemada D
Clin Exp Immunol; 2002 Sep; 129(3):471-8. PubMed ID: 12197888
[TBL] [Abstract][Full Text] [Related]
26. Anti-GAD Antibodies and the Cerebellum: Where Do We Stand?
Manto M; Mitoma H; Hampe CS
Cerebellum; 2019 Apr; 18(2):153-156. PubMed ID: 30343467
[TBL] [Abstract][Full Text] [Related]
27. GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders.
Fouka P; Alexopoulos H; Akrivou S; Trohatou O; Politis PK; Dalakas MC
J Neuroimmunol; 2015 Apr; 281():73-7. PubMed ID: 25867471
[TBL] [Abstract][Full Text] [Related]
28. Immunology of stiff person syndrome and other GAD-associated neurological disorders.
Alexopoulos H; Dalakas MC
Expert Rev Clin Immunol; 2013 Nov; 9(11):1043-53. PubMed ID: 24168411
[TBL] [Abstract][Full Text] [Related]
29. Quantitative brain imaging analysis of neurological syndromes associated with anti-GAD antibodies.
Dade M; Giry M; Berzero G; Benazra M; Huberfeld G; Leclercq D; Navarro V; Delattre JY; Psimaras D; Alentorn A
Neuroimage Clin; 2021; 32():102826. PubMed ID: 34563986
[TBL] [Abstract][Full Text] [Related]
30. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies.
Dalakas MC; Li M; Fujii M; Jacobowitz DM
Neurology; 2001 Sep; 57(5):780-4. PubMed ID: 11552003
[TBL] [Abstract][Full Text] [Related]
31. Spontaneous downbeat nystagmus as a clue for the diagnosis of ataxia associated with anti-GAD antibodies.
Vale TC; Pedroso JL; Alquéres RA; Dutra LA; Barsottini OG
J Neurol Sci; 2015 Dec; 359(1-2):21-3. PubMed ID: 26671081
[TBL] [Abstract][Full Text] [Related]
32. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies.
Dalakas MC
J Neurol; 2005 May; 252 Suppl 1():I19-25. PubMed ID: 15959668
[TBL] [Abstract][Full Text] [Related]
33. Clinical characteristics of GAD 65-associated autoimmune encephalitis.
Zhu F; Shan W; Lv R; Li Z; Wang Q
Acta Neurol Scand; 2020 Sep; 142(3):281-293. PubMed ID: 32416610
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of glutamic acid decarboxylase (GAD) 65 antibody detection methods for neurological and diabetic investigation in an Australian diagnostic laboratory.
Cecchin A; Reynolds C; Ali S; Hissaria P
Pathology; 2023 Jun; 55(4):538-542. PubMed ID: 37037719
[TBL] [Abstract][Full Text] [Related]
35. Possible link of genetic variants to autoimmunity in GAD-antibody-associated neurological disorders.
Thaler FS; Bangol B; Biljecki M; Havla J; Schumacher AM; Kümpfel T
J Neurol Sci; 2020 Jun; 413():116860. PubMed ID: 32388243
[TBL] [Abstract][Full Text] [Related]
36. Neuronal surface and glutamic acid decarboxylase autoantibodies in Nonparaneoplastic stiff person syndrome.
Chang T; Alexopoulos H; McMenamin M; Carvajal-González A; Alexander SK; Deacon R; Erdelyi F; Szabó G; Lang B; Blaes F; Brown P; Vincent A
JAMA Neurol; 2013 Sep; 70(9):1140-9. PubMed ID: 23877118
[TBL] [Abstract][Full Text] [Related]
37. [Clinical characteristics of four patients with temporal lobe epilepsy associated with elevated anti-GAD antibodies].
Akaishi T; Jin K; Kato K; Itabashi H; Misu T; Tateyama M; Iwasaki M; Aoki M; Nakasato N
Rinsho Shinkeigaku; 2015; 55(11):804-9. PubMed ID: 26369378
[TBL] [Abstract][Full Text] [Related]
38. Opsoclonus-myoclonus-ataxia syndrome with autoantibodies to glutamic acid decarboxylase.
Markakis I; Alexiou E; Xifaras M; Gekas G; Rombos A
Clin Neurol Neurosurg; 2008 Jun; 110(6):619-21. PubMed ID: 18433986
[TBL] [Abstract][Full Text] [Related]
39. Low-Titre GAD Antibody-Associated Late-Onset Cerebellar Ataxia with a Significant Clinical Response to Intravenous Immunoglobulin Treatment.
Petrijan T; Menih M
Cerebellum; 2017 Aug; 16(4):868-871. PubMed ID: 28321713
[TBL] [Abstract][Full Text] [Related]
40. Stiff-person syndrome (SPS) and anti-GAD-related CNS degenerations: protean additions to the autoimmune central neuropathies.
Ali F; Rowley M; Jayakrishnan B; Teuber S; Gershwin ME; Mackay IR
J Autoimmun; 2011 Sep; 37(2):79-87. PubMed ID: 21680149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
